Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mars 2026 12h10 HE | Source: Research and Markets

Jetrea (Oxurion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Jetrea Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
30 oct. 2025 08h35 HE | Source: Precedence Research

Diabetic Retinopathy Market Size Worth USD 17.91 Billion by 2034

Ottawa, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The global diabetic retinopathy market size is expected to be worth over USD 17.91 billion by 2034, increasing from USD 10.89 billion in 2026, growing at a...
16 juin 2025 13h00 HE | Source: DelveInsight Business Research LLP

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types

New York, USA, June 16, 2025 (GLOBE NEWSWIRE) -- Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types According to DelveInsight’s analysis, the...
22 avr. 2025 08h45 HE | Source: SNS Insider pvt ltd

Peptide and Anticoagulant Drugs Market Size to Hit USD 173.99 Billion by 2032, Driven by Rise in Chronic Illnesses and Drug Delivery Innovations | SNS Insider

Austin, April 22, 2025 (GLOBE NEWSWIRE) -- Peptide and Anticoagulant Drugs Market Size & Growth Analysis: According to SNS Insider, the Peptide and Anticoagulant Drugs Market was valued at USD...
17 avr. 2025 04h04 HE | Source: Research and Markets

Juvenile Macular Degeneration Market Report 2025: Key Players are Focusing on Innovative Treatments, Gene Therapies, Anti-VEGF Drugs and Advanced Diagnostic Tools

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "Juvenile Macular Degeneration Market" report has been added to ResearchAndMarkets.com's offering.The juvenile macular degeneration market was valued...
25 juil. 2024 12h00 HE | Source: Oxurion NV

Oxurion Share Consolidation

Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its...
24 juil. 2024 12h00 HE | Source: Oxurion NV

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical...
19 juil. 2024 12h00 HE | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR...
18 juil. 2024 12h00 HE | Source: Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
11 juil. 2024 12h00 HE | Source: Oxurion NV

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext...

Page suivante